adding glp-1 to insulin a receptor agonist was not associated with a lower likelihood of discontinuing existing basal therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation GLP-1 | Summary

Improving insulin sensitivity through GIP receptor activation while simultaneously reducing caloric intake via delayed gastric emptying and prolonged satiety

Also, in the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) study, approximately 10 thousand patients with type 2 diabetes and history of CVD or cardiovascular risk factors were randomized to a weekly subcutaneous injection of dulaglutide 1.5 mg or placebo [16]

3 Conclusion The troubling rise in the number of subjects affected by obesity worldwide has necessitated new scientific developments to blunt previous adverse effects of medication and facilitate administration, addressing different problems with a single drug

For instance, people with three or more concussions are three times more likely to develop depression compared to those without a concussion history

Eckhardt, M